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As lessons from ancient history are still pertinent in today’s 
society, the saying of the Yellow Emperor is unfortunately 
still daily practice: AF patients have a doubled mortality 
risk.
In the current issue of Netherlands Heart Journal, 
Lanters et al. [2] describe the outline of the just-started 
HALT&REVERSE project, which aims to stop and possibly 
even reverse the electromechanical remodelling that causes 
AF using heat shock proteins (HSPs). The HSPs form a 
family of cardioprotective proteins that are up-regulated 
during cellular stress and function as intracellular chaper-
ones for other proteins. They were discovered in relation 
to heat shock stress (hence the name), but they are present 
during all kinds of stress, including atrial stress. Previous 
studies in patients showed that impaired HSP expression is 
associated with AF, and HSP induction in various animal 
models resulted in atrial electrophysiological changes and 
inhibition of AF [3]. The use of HSPs and their inducers in 
the HALT&REVERSE project is therefore a very interest-
ing idea, which targets AF at its roots, potentially curing the 
pathological remodelled heart.
The overall aim of the HALT&REVERSE project cor-
responds with an increasing mind-shift in cardiovascular 
research. Instead of only focusing on treatment of symp-
toms and complications, counteracting development of the 
underlying disease to be able to cure/limit/prevent the dis-
ease substrate, sometimes even before the onset of symp-
toms, is gaining more attention. In heart failure patients with 
an intraventricular conduction delay, for example, cardiac 
resynchronisation therapy (via intervention using electri-
cal devices) is successfully used to reverse initial cardiac 
remodelling caused by altered activation [4]. Another illus-
trative example is a study by Asimaki et al. [5], investi-
gating a genetic mutation in desmosomal proteins, which 
classically leads to arrhythmogenic cardiomyopathy (also 
‘When the pulse is irregular and tremulous and the beats 
occur at intervals, then the impulse of life fades’. More than 
4000 years ago, the Yellow Emperor of China wrote this in 
his classics of internal medicine (Huang Ti Nei Ching Su 
Wen) [1], perhaps thereby describing atrial fibrillation (AF) 
for the first time. Currently, AF is the most common sus-
tained arrhythmia in Western society. Its prevalence of 1 % 
is expected to double in the next decades, primarily due to 
ageing of the population, making it a growing public health 
burden with an unacceptably high impact on quality of life. 
The pathophysiology of AF embeds a high mode of com-
plexity, and the intermingling mechanisms underlying AF 
are still incompletely understood. In short, AF consists of 
heterogeneous electromechanical remodelling of the atria in 
a concealed phase, which is followed by presentation due 
to an initiating trigger. General modes of treatment focus 
on two main aspects: (1) termination of the initiating trig-
ger, either by anti-arrhythmic medication, cardioversion, 
or ablation therapy, and (2) prevention of complications of 
AF, such as the formation of occluding thrombi or a high 
ventricular rate, which further exacerbates the pathophysi-
ological consequences. However, curative treatment of 
the electromechanical remodelling, the main cause of AF 
development, maintenance, and progression, is currently 
not possible. The major problem for accurate and effective 
treatment of remodelling is the fact that at the moment of the 
first presentation of AF, the atria are already electrically and 
structurally remodelled to an advanced pathological level. 
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known as arrhythmogenic right ventricular cardiomyopa-
thy), a disease associated with a high incidence of sudden 
arrhythmogenic death. When cardiac remodelling was phar-
macologically suppressed at an early stage, heart failure 
no longer developed, thereby treating the disease before 
its fatal onset. In this case, unravelling of the mechanism 
that initiates the cardiac remodelling, in combination with a 
sophisticated large drug-screening assay, opened doors for 
future curative therapy.
Curative treatment of the remodelled substrate in AF will 
not only support the immediate (but often short-lasting) 
success that cardioversion or ablation therapy have, but it 
also has the potential to prevent and reverse AF develop-
ment, maintenance, and progression on the longer term and 
thereby significantly reduce the AF burden for patients and 
society. Let’s hope that research on such curative thera-
peutics will finally add new ground-breaking milestones to 
medicine and become part of daily practice in AF treatment, 
so that the emperor’s wisdom, as expressed in his ancient 
documentations 4000 years ago, will truly become history.
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